First Generic Version of Gleevec Approved by FDA
(Source: WebMD Health)
Source: WebMD Health - December 7, 2015 Category: Consumer Health News Source Type: news
Sun Pharma Announces FDA Approval for Generic Gleevec
Mumbai, December 04, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma) today announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 4, 2015 Category: Pharmaceuticals Source Type: news
Sun Pharma gets boost with US FDA approval for Gleevec
Sun Pharmaceutical announced it received approval from the US FDA for generic copies of Gleevec, a drug that treats chronic myeloid leukemia. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 4, 2015 Category: Pharmaceuticals Source Type: news
UCLA study identifies potential therapeutic targets for metastatic prostate cancer
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have pinpointed five specific enzymes called protein kinases that play a role when prostate cancer spreads to bone. The discovery could point the way toward new drugs that slow or stop prostate cancer from spreading.
The findings, which were published in the journal Proceedings of the National Academy of Sciences, are particularly important because in the vast majority of men whose prostate cancer spreads, or metastasizes, the cancer reaches the bone and is much more difficult to treat. When the disease is confined to the ...
Source: UCLA Newsroom: Health Sciences - December 2, 2015 Category: Universities & Medical Training Source Type: news
Why Are Most Cancer Drugs so Expensive and so Ineffective?
Monopoly is defined as: "a situation in which a single company or group owns all or nearly all of the market for a given type of product or service. By definition, monopoly is characterized by an absence of competition, which often results in high prices and inferior products."
The pharmaceutical industry is the most powerful monopoly in the United States. Not surprisingly, it delivers mostly second-rate products at ridiculously inflated prices. The results are unprecedented profits and bad patient care.
Pharma's monopoly power is exerted in a variety of interacting domains.
Political Monoply: Big Pharma is a dominant ...
Source: Science - The Huffington Post - October 15, 2015 Category: Science Source Type: news
Genomics Moves From the Lab to the Doctor's Office
By Diana Brazzell, Co-Founder & Executive Editor, Footnote
This post was originally published on Footnote, a website that brings academic research and ideas to a broader audience.
Since the discovery of DNA, people have anticipated how deciphering the secrets in our genes might one day transform medicine. The first commonly used genetic tests appeared in the 1970s and the full human genome was sequenced in 2003. But it is only in the past decade, as sequencing technology advanced rapidly and the price tag plummeted, that genomic medicine has started to become a reality.(a) We're finally gaining access to a huge piece of ...
Source: Science - The Huffington Post - October 15, 2015 Category: Science Source Type: news
Laurie Letvak
Vice President and Head of Clinical Development Policy Dr. Laurie Letvak is Vice President and Head of Clinical Development Policy at Novartis, a position she has held since June 2014.
Laurie has been with Novartis for 20 years in a variety of positions. She played a key role in the development of Gleevec® since joining the International Project Team in 2001, responsible for Global Medical Affairs. She led the development of the Medical Affairs program, which resulted in many key studies, some of which have provided the data for new indications for Gleevec ®, including Ph+ ALL and Adjuvant GIST. From 2008-2012,...
Source: PHRMA - May 4, 2015 Category: Pharmaceuticals Authors: Ali Source Type: news
[Editors' Choice] Imatinib self-sabotages
The anticancer drug imatinib dampens its own toxicity by inducing a feedback loop that promotes proliferative signaling by fibroblast growth factor. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - April 15, 2015 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news
Anticancer drug can spur immune system to fight infection
Imatinib, an example of a 'targeted therapy' against cancer, or related drugs might be tools to fight a variety of infections, scientists say. Imatinib, is an example of a "targeted therapy" against certain types of cancer. It blocks tyrosine kinase enzymes, which are dysregulated in cancers such as chronic myelogenous leukemia and gastrointestinal stromal tumors. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 1, 2015 Category: Science Source Type: news
Anticancer drug can spur immune system to fight infection
(Emory Health Sciences) Imatinib, an example of a 'targeted therapy' against cancer, or related drugs might be tools to fight a variety of infections. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 1, 2015 Category: Global & Universal Source Type: news
Evolution may hold the key to more designer cancer drugs like Gleevec
(Brandeis University) Dorothee Kern, a professor of biochemistry and Howard Hughes Medical Institute investigator, unraveled the journey of two closely related cancer-causing proteins -- one susceptible to the drug Gleevec and one not -- over one billion years of evolution. She and her team pinpointed the exact evolutionary shifts that caused Gleevec to bind well with one and poorly with the other. This new approach may have a major impact on the development of rational drugs to fight cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2015 Category: Global & Universal Source Type: news
Could there be a gleevec for brain cancer?
(Columbia University Medical Center) The drug Gleevec (imatinib mesylate) is well known not only for its effectiveness against chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, but also for the story behinds its development. The drug was specifically designed to target an abnormal molecule--a fusion of two normal cell proteins--that fueled a tumor's growth. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 9, 2015 Category: Cancer & Oncology Source Type: news
Imatinib and Muscle Cramps: Any Remedies?Imatinib and Muscle Cramps: Any Remedies?
Many patients taking imatinib complain of muscle cramps. Can anything help? Medscape Pharmacists (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology Ask the Expert Source Type: news
Cost Savings Limited With Generic Imatinib
Imatinib ' s inflation - adjusted list price more than doubled from launch to entry of generic (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news
